Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as...

Full description

Bibliographic Details
Main Authors: HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Biobetter
biologic
biosimilar
CT-P13
infliximab
innovative biologics
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2020.1868078

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2020.1868078

Similar Items